Grantham Mayo Van Otterloo & Co. LLC Decreases Stock Holdings in Solventum Co. (NYSE:SOLV)

Grantham Mayo Van Otterloo & Co. LLC cut its stake in Solventum Co. (NYSE:SOLV) by 10.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 494,160 shares of the company’s stock after selling 59,350 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC owned 0.29% of Solventum worth $32,644,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Worldquant Millennium Advisors LLC lifted its holdings in Solventum by 373.6% in the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock valued at $3,323,000 after acquiring an additional 37,600 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in shares of Solventum by 24.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after buying an additional 9,333 shares during the last quarter. State Street Corp grew its position in Solventum by 3.1% during the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after buying an additional 185,938 shares during the period. Forsta AP Fonden purchased a new stake in Solventum during the fourth quarter valued at approximately $1,876,000. Finally, New York State Teachers Retirement System raised its position in Solventum by 4.0% in the fourth quarter. New York State Teachers Retirement System now owns 124,699 shares of the company’s stock worth $8,238,000 after acquiring an additional 4,819 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Mizuho upped their price target on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Morgan Stanley lifted their price objective on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th. Piper Sandler increased their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Finally, Bank of America lifted their price target on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Trading Down 5.7 %

Shares of SOLV opened at $66.22 on Friday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The company has a 50 day simple moving average of $75.42 and a two-hundred day simple moving average of $71.95. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a market cap of $11.45 billion and a P/E ratio of 24.08.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.